Rise Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$217K Sell
1,492
-1,302
-47% -$180K 0.06% 96
2026
Q2
$359K Buy
2,794
+43
+2% +$5.03K 0.1% 69
2026
Q1
$332K Sell
2,751
-609
-18% -$70.3K 0.12% 61
2025
Q4
$354K Sell
3,360
-380
-10% -$35.7K 0.13% 62
2025
Q3
$314K Buy
3,740
+31
+0.8% +$2.55K 0.11% 69
2025
Q2
$294K Sell
3,709
-177
-5% -$14.1K 0.12% 69
2025
Q1
$349K Sell
3,886
-722
-16% -$67.4K 0.15% 60
2024
Q4
$458K Sell
4,608
-491
-10% -$50.6K 0.22% 46
2024
Q3
$579K Sell
5,099
-180
-3% -$21.4K 0.28% 35
2024
Q2
$653K Buy
5,279
+422
+9% +$54.4K 0.35% 26
2024
Q1
$641K Buy
4,857
+1,792
+58% +$221K 0.34% 26
2023
Q4
$334K Buy
3,065
+298
+11% +$30.9K 0.23% 39
2023
Q3
$285K Sell
2,767
-1,725
-38% -$186K 0.23% 40
2023
Q2
$518K Sell
4,492
-73
-2% -$8.29K 0.4% 29
2023
Q1
$486K Buy
4,565
+383
+9% +$41.4K 0.37% 31
2022
Q4
$464K Hold
4,182
– – 0.37% 30
2022
Q3
$360K Buy
4,182
+58
+1% +$5.18K 0.3% 39
2022
Q2
$376K Buy
4,124
+451
+12% +$40K 0.38% 38
2022
Q1
$301K Buy
3,673
+678
+23% +$53.5K 0.27% 50
2021
Q4
$230K Buy
+2,995
New +$239K 0.22% 58

Other funds holding MRK

Rise Advisors's MRK Position: Q3 2026 in Review

Rise Advisors reduced its Merck (MRK) stake by 47% in Q3 2026, selling an estimated $180K and leaving 1,492 shares worth $217K. The position accounts for 0.06% of the portfolio, ranked #96.

Rise Advisors first reported a position in MRK in Q4 2021 and has held it in 20 quarters since. The position peaked at $653K in Q2 2024. 3,979 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Rise Advisors held 1,492 shares of Merck worth $217K as of Q3 2026.
  • Rise Advisors sold 1,302 Merck shares in Q3 2026, an estimated $180K.
  • Merck made up 0.06% of Rise Advisors's portfolio in Q3 2026, its #96 holding.
  • Rise Advisors first reported a position in Merck in Q4 2021 and has held it in 20 quarters since.
  • Rise Advisors's Merck position peaked at $653K in Q2 2024.
  • 3,979 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Rise Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.